Administration Can’t Be Trusted With Generic User Fees, Rep. Waxman Says
This article was originally published in The Pink Sheet Daily
Rep. Henry Waxman (D-Calif.) is opposing possible user fees for generic drug applications, arguing that the societal benefit of rapid generic entry justifies increased appropriations for the office
You may also be interested in...
GPhA says it would consider user fees for generics if FDA would endorse legislation to speed generics to the market.
Pink Sheet reporters and editor discuss the influence of the emergency use authorization on FDA decisions, another twist in the march-in rights debate, and how CBER is not using the real-time oncology review program.
America still has a long way to go to meaningfully contribute to ending the global pandemic, but loaning AstraZeneca’s vaccine to Canada and Mexico helps counter the narrative that only China and Russia are helping the rest of the world.